ARCHIVES

Two Second-Line CML Drugs Work Front-Line, Studies Find

This article is from The Cancer Letter archive.

Vol. 33 No. 1 | January 29, 2010

Download PDF Visit The Full Archive

Related Articles

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

Senate Vote On Override Of NIH Reauthorization Veto Delayed Until After US-USSR Summit Meeting

November 22, 1985

Conversation With The Cancer Letter: Hudis: ASCO Vying for Big Role in Big Data

November 22, 2013

In Brief: Big Ten Cancer Research Consortium Names Executive Officer

May 30, 2014

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

Minorities Increasingly Involved In Research, Training Programs

December 5, 1986